American Academy of Neurology (AAN) 2020 Annual Meeting

Toronto, Ontario 25 April 2020 - 01 May 2020

Aducanumab in Alzheimer’s disease: Does it work?

24 Jun 2020 by

While aducanumab significantly reduced clinical decline in individuals with early Alzheimer's disease (AD) in one randomized trial, no changes were seen in another identical study — rendering the role of aducanumab in AD inconclusive.

Aducanumab in Alzheimer’s disease: Does it work?

24 Jun 2020

Excessive sleepiness at daytime may signal heart disease, cancer, diabetes

15 Jun 2020 by

Older adults who are excessively sleepy at daytime are twice as likely as their non-sleepy counterparts to develop either heart disease, cancer, or diabetes, a new research released at AAN 2020 has shown.

Excessive sleepiness at daytime may signal heart disease, cancer, diabetes

15 Jun 2020

Multimodal approach to pain: Answer to acute migraine treatment?

12 Jun 2020 by

A new combination product (AXS-07), which consists of the triptan rizatriptan and the NSAID* meloxicam, led to rapid and sustained pain relief than treatment with either component alone or placebo in patients with a history of inadequate response to prior acute migraine treatment, according to data from the MOMENTUM study released during the AAN 2020 Meeting.

Multimodal approach to pain: Answer to acute migraine treatment?

12 Jun 2020

Risdiplam yields motor function gains for SMA babies

07 Jun 2020 by

Treatment with risdiplam helps infants with Type 1 spinal muscular atrophy (SMA) gained significant motor functions, according to the FIREFISH Part 2 pivotal trial presented during the AAN 2020 Meeting.

Risdiplam yields motor function gains for SMA babies

07 Jun 2020

Fremanezumab does not raise CV concerns, even in high-risk migraine patients

04 Jun 2020 by

Patients using the CGRP* blocker fremanezumab for migraine treatment need not worry about cardiovascular (CV) safety of the drug, as pooled data from three phase III trials showed no safety signals for CV events with the treatment, even in those with a CV medical history.

Fremanezumab does not raise CV concerns, even in high-risk migraine patients

04 Jun 2020